Toru Kondo

Dr. Toru Kondo is affiliated with the School of Cardiovascular & Metabolic Health at the University of Glasgow. His research focuses on heart failure (HF), particularly exploring outcomes and drug efficacy across ejection fraction subtypes (HFrEF, HFmrEF, HFpEF). His work emphasizes the role of dapagliflozin and other pharmacotherapies in improving clinical outcomes, quality of life, and reducing hospitalizations. He has extensively studied biomarkers, risk stratification, and geographic variability in HF patient populations.

Key research areas include: (

• Efficacy of SGLT2 inhibitors (e.g., dapagliflozin) in HF subpopulations
• Prognostic implications of natriuretic peptides and nutritional indices
• Stroke risk prediction in HF without atrial fibrillation
• Geographic and demographic disparities in HF outcomes
• Optimal dosing strategies for HF therapies

)

His publications span top journals including JACC: Heart Failure, European Heart Journal, and Nature Medicine, with a focus on translational clinical research. No scientific awards are explicitly mentioned in the provided texts.